Market Capitalization – Big Pharma - Milken Institute

More documents

Recommendations

Info

Roadblocks in Early Stage Translational Research Translational Funding Gap “Valley of Death” Post-NIH to Pre-Commercial Funding Discovery Development
Page 2 and 3: Biopharmaceuticals: The Innovation
Page 4 and 5: Market Capitalization - Big Biotech
Page 6 and 7: Big Pharma vs. Big Biotech Market C
Page 8 and 9: U.S. Biotech Industry Summary Reven
Page 10 and 11: Nasdaq Biotech vs. Nasdaq Composite
Page 12 and 13: Mean Approval Time for New Biologic
Page 14 and 15: New Breast Cancer Drug Helps Women
Page 16 and 17: US$ Billions 35 30 25 20 15 10 5 0
Page 18 and 19: Industry R&D Predominately Higher t
Page 20 and 21: Biotech Deals and Amount Raised 199
Page 22 and 23: Total Alliance Numbers and Deal Val
Page 24 and 25: Alliance Deal Activity Top Transact
Page 26 and 27: US$ Billions 400 300 200 100 0 1994
Page 28 and 29: Up to 6.5 years Up to 6 years Up to
Page 30 and 31: Biotech Products have Better U.S. A
Page 32 and 33: Clinical and Total Cost Reductions
Page 34 and 35: Years 20 15 10 5 0 Average Effectiv
Page 36 and 37: Generics’ Share of U.S Prescripti
Page 38 and 39: Medicines in Development For Heart
Page 40 and 41: Medicines in Development For Cancer
Page 44 and 45: Discovery: Target Identification Ro
Page 46 and 47: The Changing Healthcare Industry Wi
Page 48 and 49: Year 2000 Private Financings 454 Co
Page 50 and 51: $ (Millions) 250 200 150 100 50 0 I
Page 52 and 53: Health Insurance Pharmaceutical Ind
Page 54 and 55: Funding Then Now Linear funding - S
Page 56 and 57: Market Cap ($ M) The U.S. - E.U. Bi
Page 58 and 59: Large Pharma Pipeline • 1980’s
Page 60 and 61: Worldwide Life Expectancy Growth 26
Page 62: Watch the discussion again or share

Market Capitalization – Big Pharma - Milken Institute

Create successful ePaper yourself

Delete template?

Save as template?